{"id":"W1962272706","doi":"10.1093/eurheartj/ehv370","title":"ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia","year":2015,"lang":"en","type":"article","venue":"European Heart Journal","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":534,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Clinical Research Institute","funders":"Kowa Company; Esperion Therapeutics; Regeneron Pharmaceuticals; Valeant Pharmaceuticals International; Sanofi; Servier; Amgen; Pfizer; Janssen Pharmaceuticals; AstraZeneca; Eli Lilly and Company","keywords":"Alirocumab; Medicine; Placebo; Discontinuation; Internal medicine; PCSK9; Gastroenterology; Clinical endpoint; Adverse effect; Randomized controlled trial; Endocrinology; Cholesterol; Apolipoprotein B; Lipoprotein; LDL receptor; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009657728,0.0002702637,0.0004923911,0.0001527081,0.0001905038,0.00008016564,0.00007405961,0.00004600756,0.000005024108],"category_scores_gemma":[0.00005277466,0.000163302,0.00009162908,0.0001495538,0.00007748555,0.0001856383,0.0000536304,0.0004592846,0.00002639357],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002865301,"about_ca_system_score_gemma":0.0002673272,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000206448,"about_ca_topic_score_gemma":0.000100195,"domain_scores_codex":[0.997606,0.0004585203,0.0004047198,0.000366601,0.0007204165,0.0004437616],"domain_scores_gemma":[0.9985461,0.0000163461,0.0001138515,0.0004240981,0.000179604,0.0007200219],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.01589368,0.002405777,0.8774104,0.00009959398,0.0005955694,0.006194454,0.008544797,0.0001566925,0.0001547098,0.000003733267,0.004122159,0.08441848],"study_design_scores_gemma":[0.03205109,0.01522817,0.8926262,0.0004056449,0.0001173297,0.004511993,0.0003117037,0.00001311008,0.00005010099,0.000002485373,0.05444787,0.0002342752],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9954991,0.0004720385,0.00002730332,0.0007396586,0.0001316373,0.0005602891,0.00001303979,0.00003260536,0.002524298],"genre_scores_gemma":[0.9969835,0.0001261135,0.001148795,0.0005843187,0.0006158869,0.000005626977,0.00002087136,0.0000689368,0.0004458957],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0841842,"threshold_uncertainty_score":0.6659261,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04032491007896476,"score_gpt":0.2640132499836305,"score_spread":0.2236883399046657,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}